Group 1: Company Overview - Fulejia is a professional skin care product company focused on R&D, production, and sales of medical devices and functional skin care products, with a multi-channel sales strategy that includes both online and offline platforms [2][3]. - The company has established a comprehensive market reach through major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline channels including specialty cosmetics stores, large supermarkets, chain pharmacies, beauty institutions, and medical facilities [2]. Group 2: Product Registration and R&D - Fulejia has obtained 4 Class II medical device registrations, including products such as medical sodium hyaluronate repair patches and medical recombinant type III humanized collagen patches [3]. - The company has two R&D centers located in Shanghai and Harbin, focusing on raw material development and medical device product R&D, respectively [3]. - In 2025, Fulejia registered 48 cosmetic products, covering various forms such as water, lotion, cream, and essence [4]. Group 3: Clinical Trials and Product Development - The clinical trial for the recombinant type III humanized collagen freeze-dried fiber project has been completed, and the company is preparing the clinical trial summary report for registration submission [4]. - In 2025, the company completed the registration of two new raw materials, which will be developed into products to enhance the product matrix [3]. Group 4: Channel Optimization and Management - The company is optimizing its offline channels, focusing on sales channel and retail terminal improvements, with financial feedback showing some lag [4][5]. - Future strategies include strengthening partnerships with service-oriented distributors and implementing a dual approach of "strong supervision + strong optimization" to enhance market control and stabilize pricing [5]. Group 5: Management and Shareholding - Currently, there is no intention for the company's directors and senior management to reduce their holdings [5].

证券日报网讯2月2日，敷尔佳（301371）在互动平台回答投资者提问时表示，截至2026年1月30日，公 司股东户数为15642户。 ...

Core Viewpoint - On February 2, a total of 7 listed companies had their restricted shares unlocked, with a total market value of approximately 43.65 billion yuan [1] Group 1: Company Specifics - Yunding Technology (Stock Code: 000409) had 4.0062 million shares released from equity incentive restrictions [1] - Jinling Pharmaceutical (Stock Code: 000919) had 220,800 shares released from equity incentive restrictions [1] - Dongfang Chuangye (Stock Code: 600278) had 531,600 shares released from equity incentive restrictions [1] - Xinda Securities (Stock Code: 601059) had 2.551 billion shares released from pre-issue share restrictions [1] - Nuo Si Ge (Stock Code: 301333) had 3.9288 million shares with extended lock-up periods released [1] - Jianghan New Materials (Stock Code: 603281) had 12.2 million shares released from pre-issue share restrictions [1] - Fu Er Jia (Stock Code: 301371) had 250,000 shares with extended lock-up periods released [1]

Market Overview - The cosmetics sector experienced a decline of 0.98% on January 30, with Lafang Family leading the drop [1] - The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1] Individual Stock Performance - Qingdao Kingking (002094) saw a closing price of 8.75, with an increase of 4.17% and a trading volume of 1.1682 million shares, amounting to a transaction value of 1.02 billion [1] - Lafang Family (603630) closed at 19.21, down 6.38%, with a trading volume of 89,300 shares and a transaction value of 174 million [2] - Shanghai Jahwa (600315) closed at 20.92, down 4.52%, with a trading volume of 163,300 shares and a transaction value of 345 million [2] - Other notable stocks include Beitaini (300957) at 41.89, down 0.85%, and Marubi (603983) at 31.52, down 0.32% [2] Capital Flow Analysis - The cosmetics sector saw a net inflow of 60.2766 million from institutional investors, while retail investors experienced a net outflow of 62.139 million [2] - The main capital inflow was led by Qingdao Kingking with 68.098 million, while retail investors showed significant outflows across various stocks [3] - Shanghai Jahwa had a net inflow of 6.7524 million from institutional investors, but also faced a net outflow of 7.7544 million from retail investors [3]

中信证券股份有限公司 关于哈尔滨敷尔佳科技股份有限公司首次公开发行前 已发行股份部分解除限售并上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为哈尔滨敷尔 佳科技股份有限公司（以下简称"敷尔佳"、"公司"、"发行人"）首次公开发行股 票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、法规和规范性文件要求，对敷尔 佳首次公开发行前已发行股份部分解除限售并上市流通事项进行了审慎核查，核 查情况及核查意见如下： 一、首次公开发行网下配售股份概况 经中国证券监督管理委员会《关于同意哈尔滨敷尔佳科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2023]1157号）同意注册，并经深圳证券 交易所同意，公司首次公开发行人民币普通股（A股）股票40,080,000股,并于2023 年8月1日在深圳证券交易所创业板上市交易。公司首次公开发行前总股本为 360,000,000股，首次公开发行股票完成后总股本为400,080,000股，其中无限售条 件流通股 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2026-001 哈尔滨敷尔佳科技股份有限公司 关于首次公开发行前已发行股份部分解除限售并 上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"或"发行人"）本次解 除限售的股份为公司首次公开发行前已发行的部分限售股。本次解除限售的股东 数量为 1 户，股份数量为 325,000 股，占公司总股本的 0.0625%；本次可实际上 市流通的股份数量为 325,000 股，占公司总股本的 0.0625%。本次解除限售股份 的上市流通日期为 2026 年 2 月 2 日（星期一）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意哈尔滨敷尔佳科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2023]1157 号）同意注册，并经深圳证 券交易所同意，公司首次公开发行人民币普通股（A 股）股票 40,080,000 股,并 于 2023 年 8 月 1 日在深圳证券交易所创业板上市交易。公司首次公开发行前总 股本为 ...

Market Overview - The cosmetics sector experienced a decline of 1.27% on January 27, with Marubi Biotechnology leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Key performers in the cosmetics sector included: - Jiahen Home Cosmetics (300955) with a closing price of 41.47, up 6.88% and a trading volume of 73,900 shares, totaling 303 million yuan [1] - Qingdao Kingway (002094) closed at 8.24, up 3.00% with a trading volume of 569,900 shares, totaling 467 million yuan [1] - Conversely, Marubi Biotechnology (603983) closed at 31.84, down 4.47% with a trading volume of 46,400 shares, totaling 149 million yuan [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 43.98 million yuan from main funds, while retail investors contributed a net inflow of 43.99 million yuan [2] - Notable capital flows included: - Qingdao Kingway (002094) with a net inflow of 22.70 million yuan from main funds [3] - Shanghai Jahwa (600315) with a net inflow of 8.10 million yuan from main funds [3] - Marubi Biotechnology (603983) experienced a slight net outflow of 94,800 yuan from main funds [3]

Core Viewpoint - The OTC channel presents significant opportunities for beauty brands, offering professional endorsements, precise targeting of skincare needs, and immediate product experiences, but it also poses challenges due to strict professional requirements and a talent shortage in the industry [1][2][3]. Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, marking it as the "Year of Domestic Beauty OTC Layout" [2]. - Leading domestic beauty brand Proya (603605.SH) announced its entry into the OTC channel in January 2026, joining a growing list of companies [2]. - Brands like Winona and Kefu Beauty have been early entrants into the OTC channel, with Winona's sales nearing 1 billion yuan in 2023, capturing over 60% of the market share in this channel [5]. Group 2: Strategic Developments - In April 2025, Furuida Bio announced plans to accelerate its OTC channel development, aiming to cover 10,000 drugstore chains and launch 100 "cosmetic and medicinal" SKUs [5]. - Companies are increasingly focusing on integrating with the professional environment of pharmacies rather than merely distributing products [5]. - Proya is preparing multiple products for the OTC channel, emphasizing the importance of medical device products as a foundation for entry [6]. Group 3: Market Potential and Challenges - The OTC channel has approximately double the growth potential, with Winona targeting to cover 250,000 pharmacies [8]. - As of December 2024, there are about 705,000 licensed drug retail enterprises in China, with Winona covering over 110,000, representing about one-seventh of the total retail pharmacy stores [9]. - The demand for beauty products in pharmacies is rising due to pressures on traditional pharmacy profits and the need for transformation [9]. Group 4: Profitability and Talent Shortage - Medical device products have a significantly higher gross margin, averaging 77%-83%, compared to regular cosmetic products [9]. - The beauty industry faces a talent shortage in the pharmacy channel, as many brands rely on pharmacists who must understand both pharmaceuticals and cosmetics [10]. - Companies like Betaini are addressing this by training pharmacy staff to enhance customer trust and provide professional consultations [10][11].

Group 1 - The cosmetics sector experienced a rise of 1.34% on January 23, with Jiaheng Jiahua leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Jiaheng Jiahua's stock price increased by 7.69% to 40.06, with a trading volume of 61,900 shares and a transaction value of 242 million yuan [1] Group 2 - The cosmetics sector saw a net outflow of 35.35 million yuan from institutional investors, while retail investors had a net inflow of 31.72 million yuan [2] - Key stocks in the sector included Qingdao Jinwang, which had a net inflow of 13.85 million yuan from institutional investors, but a net outflow of 21.21 million yuan from speculative funds [3] - Jiaheng Jiahua had a net inflow of 11.11 million yuan from institutional investors, but also saw a net outflow of 1.77 million yuan from speculative funds [3]

证券日报网讯1月21日，敷尔佳（301371）在互动平台回答投资者提问时表示，截至2026年1月20日，公 司股东户数为15710户。 ...